WE ARE GOING DOWN THE WRONG PATH! THE CURRENT AASLD GUIDANCE MISCLASSIFIES MAJORITY OF PATIENTS WITH MASLD AND SIGNIFICANT FIBROSIS
<div><p><b>Background:</p> </b><p style="font-weight: 400;">Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) has extremely high prevalence in the US and globally with increasing incidence of morbidity and mortality in the population.